On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.
Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."
Data provided by Nasdaq. Minimum 15 minutes delayed.
May 17, 2018
Nuvectra to Present at Two Upcoming Investor Conferences
PLANO, Texas, May 17, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at two upcoming investor conferences in June 2018. Event: Jefferies 2018 Global Healthcare Conference
May 02, 2018
Nuvectra™ Reports First Quarter 2018 Financial Results
PLANO, Texas, May 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2018. Highlights Reported consolidated revenues of $10.6 million for the first quarter 2018, including total Algovita® sales of $9.1 million. Expanded U.S. commercial team. Completed follow-on public offering of common stock for gross proceeds of approximately $26.0 million in February
The Ruth Group